Do CJC-1295, Ipamorelin, and MK-677 Actually Improve Lean Mass or Visceral Fat in Athletes, or Is the 2026 Evidence Still Mostly Animal Data?

Mostly animal data, with one narrow human exception. A 2026 UCLA Health review of 565 studies across six unapproved peptides concluded that human evidence is sparse and marketing claims substantially outpace the clinical record. MK-677 has the strongest human dataset, but its one meaningful RCT enrolled elderly adults rather than athletes, and total fat mass rose alongside lean-mass gains.

What Did the 2026 UCLA Review Actually Find Across 565 Studies?

The UCLA Health team screened 565 published studies covering BPC-157, TB-500, CJC-1295, MK-677, ipamorelin, and GHK-Cu. Their central finding: the overwhelming majority of evidence is preclinical, human trials are absent or severely underpowered for body-composition endpoints, and safety signals in humans remain uncharacterised. For CJC-1295 and ipamorelin, no RCT has measured lean mass or visceral fat as a primary endpoint.

The review's framing is critical for performance practitioners: elevated GH and IGF-1 are proxies, not outcomes. Decades of GH replacement research in GH-deficient adults show that hormonal normalisation does not automatically produce proportional lean-mass gains in individuals who are not GH-deficient to begin with. Available human data for CJC-1295 and ipamorelin confirm only that the compounds raise GH and IGF-1, not that those hormonal changes translate into measurable body-composition shifts.

The review was led by Dr. Thomas Kremen and published in September 2026. It represents the largest simultaneous literature sweep yet performed on this compound class, and its conclusions align with the FDA's existing unapproved status for all six peptides reviewed.

What Is the Human Evidence Ceiling for CJC-1295?

CJC-1295's entire human evidence base is two pharmacokinetic trials from 2006. The Teichman study confirmed that CJC-1295 with DAC extends GH half-life to 6-8 days and raises IGF-1 by 28-43% above baseline. Neither trial measured lean mass, fat mass, or athletic performance. The human evidence ceiling is fixed at hormonal biomarker data from two small PK studies.

A 2006 rodent study using once-daily CJC-1295 found that relative lean mass and subcutaneous fat mass remained normal in all treated groups, a result frequently misread as a positive body-composition signal. Normal lean mass in a growing rodent is not equivalent to lean-mass accretion in a trained adult human. The compound's development was halted by ConjuChem after early-phase work, and no pharmaceutical sponsor has advanced it toward efficacy trials.

No phase II or phase III trial of CJC-1295 for body composition has been registered or completed as of 2026. The human evidence ceiling is therefore structural rather than a matter of pending data, because the trials simply do not exist.

Where Does the Ipamorelin Body-Composition Data Gap Begin?

Ipamorelin's body-composition data gap begins at the species boundary. Its selectivity for GH release over cortisol and prolactin was established in rat and pig models. A 2020 review found no significant changes in body weight, BMI, lean mass, or fat percentage attributable to ipamorelin in human subjects. No human RCT has tested it for body-composition endpoints.

Ipamorelin acts as a selective ghrelin-receptor agonist, stimulating pulsatile GH release without the cortisol co-elevation seen with GHRP-2 and GHRP-6. In rodent models, this selectivity produces cleaner anabolic signalling. The translation problem is that rodent GH physiology differs substantially from human GH physiology, as pulse frequency, receptor density, and downstream IGF-1 sensitivity all diverge in ways that make rodent body-composition outcomes unreliable predictors of human outcomes.

The frequently cited combination of CJC-1295 plus ipamorelin, marketed as producing additive GH pulses, has no dedicated human RCT measuring body composition. The mechanistic rationale is plausible because a GHRH analog and a ghrelin-receptor agonist act on different receptor populations. However, mechanistic plausibility is not efficacy data in an athletic population.

MK-677: What Does the Strongest Human Dataset Actually Show?

MK-677 (ibutamoren) has the most robust human body-composition data of the three, anchored by the Nass 2008 12-month RCT in elderly adults (mean age 69, n=65). Fat-free mass increased by 1.6 kg relative to placebo, but total fat mass also rose in both groups. Fasting glucose increased significantly, a metabolic cost rarely foregrounded in athlete-facing marketing.

The Nass 2008 trial population matters enormously for performance interpretation. Elderly adults with age-related GH decline are a mechanistically different target than trained athletes with intact GH axes. In GH-sufficient individuals, exogenous GH secretagogue stimulation produces diminishing returns on lean-mass accretion because the GH-IGF-1-mTOR pathway is already operating near its physiological ceiling under training stimulus.

A 2022 study in the Journal of Physiology examined co-administration of LGD-4033 and MK-677 in resistance-trained men. Body mass, lean mass, and fat mass all increased, but so did adverse lipid changes and liver enzyme elevations. The LGD-4033 confound makes it impossible to attribute body-composition changes to the ghrelin mimetic alone.

Is There Any Visceral-Fat-Specific Evidence for These Three Compounds?

Visceral-fat-specific data for CJC-1295 and ipamorelin in humans is essentially nonexistent. MK-677 data from the Nass 2008 trial used DXA for regional body composition but did not report visceral adipose tissue volume separately. No imaging-confirmed VAT reduction has been demonstrated for any of the three compounds in a controlled human trial as of 2026.

The contrast with tesamorelin, an FDA-approved GHRH analog, is instructive. Tesamorelin's VAT-reduction evidence base includes multiple Phase III RCTs with MRI-confirmed visceral fat measurements, showing 15-20% VAT reduction over 26 weeks in HIV-associated lipodystrophy. CJC-1295 is also a GHRH analog, but it has never been subjected to equivalent trial design. Extrapolating tesamorelin's VAT data to CJC-1295 is a class-effect assumption without direct support.

GH-axis activation does preferentially mobilise visceral adipose tissue in GH-deficient populations, which is mechanistically established. The unresolved question is whether supraphysiological GH pulsing in GH-sufficient athletes produces the same depot-selective lipolysis, or whether it primarily drives IGF-1-mediated anabolism with a less favourable fat-distribution outcome.

Why Does Animal Data Not Transfer Cleanly to Athletic Body Composition?

Three structural differences between rodent and human GH physiology explain most of the translation failure. Rodents have a near-continuous GH secretion pattern, while humans have discrete nocturnal pulses with longer inter-pulse troughs. Rodent skeletal muscle expresses higher GH receptor density relative to body mass. Rodent adipose tissue responds to GH-axis stimulation with faster lipolytic kinetics than human visceral fat depots.

These differences mean that a rodent body-composition result cannot be directly converted into a human effect size. The magnitude of lean-mass gain in a rodent model routinely exceeds what the same compound produces in humans by a factor of two to five, based on comparisons across compounds where both datasets exist. For performance practitioners, preclinical data establishes mechanism plausibility, not outcome magnitude.

A compound that increases lean mass by 8% in a rodent model may produce 1-2% in a human, or nothing measurable above training noise. The direction of the effect is also not guaranteed to hold across species for all endpoints, particularly for visceral fat, where human depot-specific regulation diverges most sharply from rodent models.

What Metabolic Risk Signals Appear in the Human Record?

The clearest human safety signal for this compound class is insulin resistance. The Nass 2008 MK-677 trial recorded statistically significant increases in fasting glucose and HbA1c at 12 months. GH-axis activation drives hepatic glucose output and reduces peripheral insulin sensitivity through a well-characterised post-receptor mechanism, a risk amplified in individuals carrying metabolic syndrome features or operating in caloric surplus.

For CJC-1295, the Teichman 2006 trial reported injection-site reactions and transient facial flushing as the primary adverse events. No glucose or insulin data were systematically collected, which is a significant gap given the compound's sustained GH-elevating profile. A compound that maintains elevated GH for 6-8 days per injection creates a prolonged insulin-resistance window that a pulsatile secretagogue does not.

Ipamorelin's human safety record is thin by virtue of having almost no human trial data at all. The absence of adverse event reports is not evidence of safety, but rather reflects the absence of trials. The UCLA review flagged this explicitly: for several of the six compounds reviewed, the safety profile in humans is simply unknown because the studies have not been conducted.

What Does the Evidence Gap Mean for Performance Practitioners in 2026?

Any body-composition claim for CJC-1295 or ipamorelin in athletes is currently extrapolated from hormonal biomarker data and animal studies. MK-677 has one human RCT with a lean-mass signal, but in an elderly population with a concurrent fat-mass increase and glucose-tolerance cost. Practitioners should treat the mechanistic rationale as hypothesis-generating, not as a substitute for efficacy data in their target population.

The FDA's unapproved status for all three compounds is directly tied to this evidence gap. Regulatory approval requires demonstration of efficacy and safety in the target population through controlled trials, a standard none of these three compounds has met for body-composition endpoints. The 2026 UCLA review reinforces that the gap between marketing claims and clinical evidence reflects a structural absence of trials, not a lag in pending data.

Tesamorelin, the FDA-approved GHRH analog with a genuine VAT-reduction evidence base, represents the closest validated comparator for understanding what a GHRH analog can and cannot do in humans. For practitioners who track body-composition outcomes numerically, that approved compound's trial record is the most defensible benchmark available when evaluating unapproved GHRH analogs and ghrelin mimetics. Which of the Seven Peptides Reviewed by the FDA's July 2026 Advisory Panel Have Sufficient Human Safety and Efficacy Data to Justify Compounding? Which GLP-1/GIP Combination Peptide Protocols Best Preserve Lean Mass While Improving Glycemic Control in 2026 Self-Experimentation? What New Human Safety Data Exist for BPC-157 in Musculoskeletal Recovery and Gut Repair in 2026?